Novo Holdings
VC · Copenhagen (Denmark)
Sign up free to access full profile and submit your pitch.
About
Novo Holdings A/S is the holding and investment company responsible for managing the assets of the Novo Nordisk Foundation, one of the world's largest enterprise foundations. Established in 1999, the company is headquartered in Copenhagen, Denmark, with offices in London, San Francisco, Boston, Singapore, and Shanghai. As of 2024, Novo Holdings manages total assets of DKK 1,060 billion (€142 billion). The company's primary objective is to improve people's health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation. To achieve this, Novo Holdings invests in life science companies at all stages of development and manages a diversified portfolio that includes equities, bonds, real estate, infrastructure assets, and private equity investments. In 2024, Novo Holdings reported record total income and investment returns of DKK 60 billion (€8.0 billion), driven by strong performances from its investment portfolio and the Novo Group companies. A significant recent development was the completion of a $16.5 billion acquisition of Catalent, a contract drug manufacturer, in December 2024. This strategic move aims to bolster the production of Wegovy, a popular weight-loss drug, to meet increasing demand. Novo Holdings' investment areas include life science investments, capital investments, and planetary health investments, with a focus on regions such as North America, Europe, and Asia. The company's guiding principles emphasize high performance with respect and responsibility, an ambitious strategy focused on return-driven investments, and excellence in operations, including talent development and strong governance.
Visit website ↗Investment Criteria
Sign up free to see full investment criteria and submit your pitch.
Co-Investors of Novo Holdings
Other investors that have backed the same portfolio companies as Novo Holdings. Expand any entry to see the shared portfolio companies.
- 22 shared
Shared portfolio companies
- Adaptimmune Therapeutics plc
- Adcendo ApS
- Alentis Therapeutics AG
- Asceneuron SA
- Convergent Therapeutics, Inc.
- Corvus Pharmaceuticals, Inc.
- Crinetics Pharmaceuticals, Inc.
- Disc Medicine, Inc.
- Edgewise Therapeutics, Inc.
- Galecto, Inc.
- iECURE, Inc.
- Lysogene S.A.
- Magenta Medical LTD
- Minervax ApS
- NeRRe Therapeutics Ltd.
- ObsEva SA
- OnCusp Therapeutics, Inc.
- SI-BONE, Inc.
- Terremoto Biosciences, Inc.
- TherAchon SAS
- Windward Bio AG
- Xenon Pharmaceuticals Inc.
- 20 shared
Shared portfolio companies
- Adaptimmune Therapeutics plc
- Adcendo ApS
- Alentis Therapeutics AG
- Bluejay Therapeutics, Inc.
- Claris Biotherapeutics, Inc.
- Convergent Therapeutics, Inc.
- Crinetics Pharmaceuticals, Inc.
- Edgewise Therapeutics, Inc.
- Galecto, Inc.
- Galera Therapeutics, Inc.
- Hemab ApS
- IO Biotech ApS
- KalVista Pharmaceuticals, Inc.
- Lexeo Therapeutics, Inc.
- Magenta Medical LTD
- Merus N.V.
- Metagenomi, Inc.
- Nkarta, Inc.
- Obsidian Therapeutics, Inc.
- Spero Therapeutics, Inc.
- 13 shared
- 12 shared
- 9 shared
Shared portfolio companies
- 7TM Pharma A/S
- Chromologics ApS
- Draupnir Bio Aps
- Evosep ApS
- Galecto, Inc.
- Reapplix ApS
- Reduced ApS
- Sparrow Quantum Aps.
- Strategic Partners A/S
- 9 shared
Shared portfolio companies
- 9 shared
Shared portfolio companies
- 8 shared
Shared portfolio companies
.png)
